
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is well-situated for long-term growth, with strong organic revenue growth driven by their musculoskeletal solutions and enabling technologies businesses, and a presence in both the United States and international markets. Additionally, the company's financials are strong, with reported earnings beats and margin expansion. Their diversified product offerings, including their spinal robotics platform, ExcelsiusGPS, are driving market share gains and attracting new customers. Factors such as the increasing demand for spinal robotics and the company's expansion into other medical fields, such as trauma and large joint robotics, provide further upside potential for Globus Medical's growth and profitability.
Bears say
Globus Medical is experiencing a decrease in revenue due to integration initiatives impacting their sales and marketing teams, and this is expected to continue throughout the year. Additionally, there is uncertainty surrounding their merger with NuVasive and potential competition from larger medical device companies. This, coupled with potential staffing shortages and macroeconomic headwinds, may result in a decline in revenue and margins, leading to a negative outlook on their stock.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares